Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-28T04:46:29.441Z Has data issue: false hasContentIssue false
  • English
  • Français

Impact of Clostridioides difficile infection on patient-reported quality of life

Published online by Cambridge University Press:  07 October 2021

Zheyi Han ,
Brittany Lapin ,
Kevin W. Garey ,
Curtis J. Donskey  and
Abhishek Deshpande
Zheyi Han
Affiliation:
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio
Brittany Lapin
Affiliation:
Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
Kevin W. Garey
Affiliation:
University of Houston College of Pharmacy, Houston, Texas
Curtis J. Donskey
Affiliation:
Geriatric Research Education and Clinical Center, Louis Stokes Cleveland Veterans’ Affairs Medical Center, Cleveland, Ohio
Abhishek Deshpande*
Affiliation:
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio Medicine Institute Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio
*
Author for correspondence: Abhishek Deshpande, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

We investigated the quality of life (QoL) of patients hospitalized with C. difficile infection (CDI).

Design:

Prospective survey study.

Setting:

US tertiary-care referral center, acute-care setting.

Participants:

Adults hospitalized with a diagnosis of CDI, defined as ≥3 episodes of unformed stool in 24 hours and a positive laboratory test for C. difficile.

Methods:

We surveyed patients from July 2019 to March 2020 using the disease-specific Cdiff32 questionnaire and the generic PROMIS GH survey. We compared differences in Cdiff32 scores among demographic and clinical subgroups (including CDI severity, CDI recurrence, and various comorbidities) using 2-sample t tests. We compared PROMIS GH scores to the general population T score of 50 using 1-sample t tests. We performed multivariable linear regression to identify predictors of Cdiff32 scores.

Results:

In total, 100 inpatients (mean age, 58.6 ±17.1 years; 53.0% male; 87.0% white) diagnosed with CDI completed QoL surveys. PROMIS GH physical health summary scores (T = 37.3; P < .001) and mental health summary scores (T = 43.4; P < .001) were significantly lower than those of the general population. In bivariate analysis, recurrent CDI, severe CDI, and number of stools were associated with lower Cdiff32 scores. In multivariable linear regression, recurrent CDI, severe CDI, and each additional stool in the previous 24 hours were associated with significantly decreased Cdiff32 scores.

Conclusions:

Patients hospitalized with CDI reported low scores on the Cdiff32 and PROMIS GH, demonstrating a negative impact of CDI on QoL in multiple health domains. The Cdiff32 questionnaire is particularly sensitive to QoL changes in patients with recurrent or severe disease.

Keywords

Clostridioides difficilequality of lifesurveypatient-reported outcomes
Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 43 , Issue 10 , October 2022 , pp. 1339 - 1344
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

PREVIOUS PRESENTATION: Data from this study were presented at the 2020 Society for Medical Decision Making 42nd Annual North American Meeting, October 6–27, 2020, in Chicago, Illinois.

References

Magill, SS, Edwards, JR, Bamberg, W, et al. Multistate point-prevalence survey of health care–associated infections. N Engl J Med 2014;370:1198–1208.Google ScholarPubMed
Magill, SS, O’Leary, E, Janelle, SJ, et al. Changes in prevalence of healthcare–associated infections in US hospitals. N Engl J Med 2018;379:1732–1744.CrossRefGoogle Scholar
Konijeti, GG, Sauk, J, Shrime, MG, Gupta, M, Ananthakrishnan, AN. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014;58:1507–1514.Google ScholarPubMed
Stranges, PM, Hutton, DW, Collins, CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value in Health 2013;16:297–304.CrossRefGoogle ScholarPubMed
Bartsch, SM, Curry, SR, Harrison, LH, Lee, BY. The potential economic value of screening hospital admissions for Clostridium difficile . Eur J Clin Microbiol Infect Dis 2012;31:3163–3171.CrossRefGoogle ScholarPubMed
Wilcox, MH, Ahir, H, Coia, JE, et al. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life. J Antimicrob Chemother 2017;72:2647–2656.CrossRefGoogle ScholarPubMed
Heinrich, K, Harnett, J, Vietri, J, Chambers, R, Yu, H, Zilberberg, M. Impaired quality of life, work, and activities among adults with Clostridium difficile infection: a multinational survey. Dig Dis Sci 2018;63:2864–2873.CrossRefGoogle ScholarPubMed
Barbut, F, Galperine, T, Vanhems, P, et al. Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting. Health Qual Life Outcomes 2019;17(1):6.CrossRefGoogle Scholar
Garey, KW, Aitken, SL, Gschwind, L, et al. Development and validation of a clostridium difficile health-related quality-of-life questionnaire. J Clin Gastroenterol 2016;50:631–637.CrossRefGoogle ScholarPubMed
Hays, RD, Bjorner, JB, Revicki, DA, Spritzer, KL, Cella, D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res 2009;18:873–880.CrossRefGoogle ScholarPubMed
Liu, H, Cella, D, Gershon, R, et al. Representativeness of the patient-reported outcomes measurement information system internet panel. J Clin Epidemiol 2010;63:1169–1178.CrossRefGoogle ScholarPubMed
McDonald, LC, Gerding, DN, Johnson, S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66(7):e1–e48.CrossRefGoogle Scholar
Thompson, NR, Lapin, BR, Katzan, IL. Mapping PROMIS Global Health items to EuroQol (EQ-5D) utility scores using linear and equipercentile equating. Pharmacoeconomics 2017;35:1167–1176.CrossRefGoogle ScholarPubMed
Seneviratne, MG, Bozkurt, S, Patel, MI, et al. Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer. Cancer 2019;125:943–951.Google ScholarPubMed
Shaw, BE, Syrjala, KL, Onstad, LE, et al. PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 2018;124:841–849.CrossRefGoogle ScholarPubMed
Lam, KH, Kwa, VIH. Validity of the PROMIS-10 Global Health assessed by telephone and on paper in minor stroke and transient ischaemic attack in the Netherlands. BMJ Open 2018;8(7):e019919.CrossRefGoogle ScholarPubMed
Katzan, IL, Lapin, B. PROMIS GH (Patient-Reported Outcomes Measurement Information System Global Health) scale in stroke. Stroke 2018;49:147–154.CrossRefGoogle ScholarPubMed
Kasturi, S, Szymonifka, J, Berman, JR, et al. Responsiveness of PROMIS Global Health short form in outpatients with systemic lupus erythematosus. Arthrit Care Res 2020;72:1282–1288.Google ScholarPubMed
Lapin, B, Davin, S, Stilphen, M, Benzel, E, Katzan, IL. Validation of PROMIS CATs and PROMIS Global Health in an interdisciplinary pain program for patients with chronic low back pain. Spine 2020;45(4):E227.CrossRefGoogle Scholar
Stark, RG, Reitmeir, P, Leidl, R, König, H-H. Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflamm Bowel Dis 2010;16:42–51.CrossRefGoogle ScholarPubMed
Wang, YT, Lim, HY, Tai, D, et al. The impact of irritable bowel syndrome on health-related quality of life: a Singapore perspective. BMC Gastroenterol 2012;12:104.CrossRefGoogle ScholarPubMed
Weaver, FM, Trick, WE, Evans, CT, et al. The impact of recurrent Clostridium difficile infection on patients’ prevention behaviors. Infect Control Hosp Epidemiol 2017;38:1351–1357.CrossRefGoogle ScholarPubMed
Supplementary material: File

Han et al. supplementary material

Figures S1-S2 and Tables S1-S3

Download Han et al. supplementary material(File)
File 31.3 KB